Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Insights from 2023 WCLC
S

WCLC 2023 Insights: "MSI and MMR-D Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High TMB, and MLH1 Inactivation"

By Insights from 2023 WCLC FEATURING Soo-Ryum Yang
By Insights from 2023 WCLC FEATURING Soo-Ryum Yang
119 views
November 17, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
Lung
16:46

ASCO® 2024 Insights: "NRG-LU002 Trial - Maintenance Systemic Therapy…

2024 ASCO® Annual Meeting Insights Hub

P. Iyengar

80 views
14:26

Radiation for Unresectable NSCLC: Where Are We Now and Where Are We …

Memorial Sloan Kettering Cancer Center

D. Gomez

148 views
26:21

NSCLC & Targeted Therapy: A Brief Overview and Update in the Metasta…

Memorial Sloan Kettering Cancer Center

M. Hwang

993 views
14:52

Advances in Resectable NSCLC

Memorial Sloan Kettering Cancer Center

K. Gray

151 views
09:38

ESMO 2023 Insights: "CDC7 Inhibition Constrains Lineage Plasticity a…

Insights from 2023 ESMO Annual Meeting

A. Quintanal-Villalonga

275 views
06:04

ESMO 2023 Insights: "Durable Efficacy of Zenocutuzumab, a HER2 x HER…

Insights from 2023 ESMO Annual Meeting

A. Schram

90 views
14:02

WCLC 2023 Insights: "MSI and MMR-D Define a Distinct Subset of Lung …

Insights from 2023 WCLC

S. Yang

119 views
10:18

Additional Advances in Squamous NSCLC Research and Clinical Trials

i3 Health

M. Kris

110 views
08:03
i3 Health

New Perspectives on Diagnosis and Treatment of EGFR Exon 20 Insertio…

Feat. H. Yu, M. Arcila
10:16

2021 ASCO Updates on KEYLYNK-013 Study for Newly Diagnosed LS-SCLC: …

Memorial Sloan Kettering Cancer Center

A. Rimner

252 views
05:59

2021 ASCO Updates on METex14 Skipping mNSCLC: ctDNA Dynamics & Resis…

Memorial Sloan Kettering Cancer Center

P. Paik

171 views
20:40

Can TTFields with Chemotherapy Improve Clinical Outcome in the First…

Memorial Sloan Kettering Cancer Center

C. Simone II

114 views
17:52

Malignant Pleural Mesothelioma: What Do Clinical Trials Suggest on A…

Memorial Sloan Kettering Cancer Center

M. Zauderer

266 views
16:53

Should We Combine EGFR TKIs With Upfront Radiation Therapy in EGFR+ …

Memorial Sloan Kettering Cancer Center

K. Beal

205 views
21:24

Is There a Role for IO in EGFR+ Metastatic Lung Cancer?

GRACE

H. Yu

4.8K views
19:58

Current Practice & Challenges in Execution of Genomic Testing in Adv…

Beacon Medical Interchange

J. West, G. Riely

319 views
28:12

Should Local Ablation Therapy in Oligometastatic or Oligoprogressing…

Beacon Medical Interchange

J. West, G. Riely

25 views
23:26

EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC

GRACE

H. Yu

179 views
09:30

Q&A on EGFR Initial Treatment and Acquired Resistance in Advanced NS…

GRACE

H. Yu

33 views
07:39

ES-SCLC 2020 Update: Which IO Options Showed Activity in Phase III T…

Nebraska Oncology Society

G. Riely

93 views
16:08

Stage IV NSCLC 2020 Update: Is There a Benefit to Short-Course Chemo…

Nebraska Oncology Society

G. Riely

122 views